NCT01468168View on ClinicalTrials.gov

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Dry Eye Disease
Interventions
DRUG

DE-101 Ophthalmic Suspension

Ophthalmic suspension; QID

DRUG

DE-101 Ophthalmic Suspension

Ophthalmic suspension; QID

DRUG

DE-101 Ophthalmic Suspension Vehicle

Ophthalmic suspension vehicle; QID

Trial Locations (13)

23507

Norfolk

27262

High Point

30076

Roswell

30260

Morrow

33773

Largo

44115

Cleveland

63090

Washington

63131

St Louis

64111

Kansas City

80134

Parker

84107

Salt Lake City

92663

New Port Beach

04401

Bangor

All Listed Sponsors
lead

Santen Inc.

INDUSTRY

NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients | Biotech Hunter | Biotech Hunter